Skip to main content
Donate

Angelman Syndrome News

Sort by category

Inside INSYNC-AS 2025: Progress, Partnership, and Possibilities for Angelman Syndrome

Charlie's Angels Chari-Tee Golf Tournament: A Day of Hope, Community, and Action

The LaMuras organized Rally for a Cure, a Tennis-Themed Event that Brought Together Their Community

Oak Hill Bio Announces Publication of Rugonersen Phase 1 Study Results in Nature Medicine

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Investing in the Future of Angelman Syndrome Research: FAST Partners with ASGCT to Support Early-Career Scientists

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

FAST Announces Funding For First Innovative Seed Grant

Leading Neurology and Rare Disease Expert Dr. Nick France Joins FAST Board

CAN SPOTLIGHT: Skating Angels Charity Ice Hockey Tournament

More Than a Seat at the Table: FAST’s Role in Shaping the Future of Angelman Syndrome at ASGCT 2025

CAN Spotlight: Kettlebells for Kayleigh Fundraiser in Germany

MavriX Bio Announces FDA Clearance of IND Application to Initiate First-in-Human Study of Gene Therapy for Angelman Syndrome

FAST Speaks at the 2025 MENA Congress for Rare Diseases

Expanding the Pre-Clinical Research Landscape for Angelman Syndrome

Oak Hill Bio to continue the development of rugonersen, an investigational ASO previously owned by Roche.

CAN Spotlight: Bike 4 Briar Starts May 27th!

FAST-funded researcher highlights the involvement of UBE3A in different neurodegenerative diseases

Progress for Angelman Syndrome Relies on a Strong NIH and FDA

IONIS REVEAL Phase 3 Clinical Trial Update

Exciting Announcement: Launch of Our New Electronic Journal

Community Update: New Insights into Health and Prevention in Angelman Syndrome

The Economic Burden of Caring for Individuals with Angelman Syndrome

CAN Spotlight: Matthew Gocker continues to support AS Family in Wisconsin!

Introducing the Angelman Syndrome Global Community Advisory Board (CAB)

International Angelman Day 2025: Round-Up

FAST Poland Organized the 1st Polish National Angelman Syndrome Conference

FAST Italy Hosts Its First Scientific Symposium on Angelman Syndrome

A high sensitivity assay of UBE3A ubiquitin ligase activity from Dr. Albert Keung’s Lab

2025 AS Congressional Advocacy Day: Legislative Priorities

FAST announces the launch of two biotech companies to advance investigational gene-targeted therapies for Angelman syndrome

CAN Spotlight: Raye’s Birthday Fundraiser

February 2025: Advocacy updates and actions to take

FAST-Affiliated Research Program at UCLA is awarded $5.8M to advance gene therapy for Angelman syndrome.

Introducing the Innovation Seed Grant: Supporting Early-Stage Angelman Syndrome Research

CAN Community Spotlight: Joelene

FAST Germany’s Wachgeküsst campaign

Update on Advocacy Efforts and Ways to Get Involved in 2025

Ultragenyx Announces First Patient(s) Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

FAST Spain Awards First Research Grant

FAST and ASF Advocate for Crucial Legislation

CAN Spotlight: Paddle Party for a Purpose

CAN Spotlight: 2nd Annual Hole Out Fore Heath Golf Tournament

FAST and ASF Announce their Partnership with the Institute for Gene Therapies

RSVP for the January 2025 EL-PFDD Meeting

2024 Global Science Summit Recap

Ionis Pharmaceuticals releases information on their planned phase 3 clinical trial for Angelman syndrome

CAN Spotlight: Remi Cup 2024

The PFDD Survey is now open

Watch the Clinical Trials 101 Video

Watch the ASF | FAST Ultragenyx Community Webinar recording

FAST UK hosts Art for Angelman 2024

CAN Spotlight: Bike for Briar’s MEGA Meat Raffle

CAN Spotlight: All in for Olin Fundraiser

Ultragenyx Community Update October 2024

CAN Spotlight: Friends of James Oktoberfest

CAN Spotlight: Maddie's Mission 3rd Annual Block Party Tailgate

CAN Spotlight: 100 mile Coast to Coast Triathlon for Angelman Syndrome

CAN Spotlight: Granville Angels 2nd Annual Cornhole for a Cause

CAN Spotlight: 4th Annual Charlie’s Angels Chari-Tee Golf Tournament

2024 Global Science Summit Sneak Peeks

Celebrating the First Angelman Syndrome Congress in Latin America: A Milestone for FAST Latam

Tell Congress to support vital programs that impact our community

Developmental milestones and daily living skills in individuals with Angelman syndrome

FAST Gains New Leaders on Board and Council

CAN Spotlight: Joe Bologna’s 4th Annual Charity Golf Outing

ASF and FAST applaud the establishment of FDA Rare Disease Innovation Hub

FAST attends the 8th ASA Congress: A Collaborative Step Forward

FAST Gala Hair & Makeup Experience by Making Up Las Vegas

CAN Spotlight: 2nd Annual, “If Will CAN, We CAN” fundraiser

Neuren Pharmaceuticals announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Angelman syndrome (AS). 

AS Advocates Achieve Initial Wins Resulting from Inaugural Congressional Advocacy Day

Hope in Action: Angelman Syndrome PFDD Meeting January 2025

CAN Spotlight: Always Having Fun Foundation hosts their 7th annual Golf Tournament

CAN Spotlight: 6th Annual Links for Louie Charity Golf Tournament

Welcome Michele Golombuski, FAST’s inaugural Chief Development Officer

Exciting News from UPenn

CAN Spotlight: Payslie’s Pals 3rd Annual Cornhole Tournament Fundraiser

CAN Spotlight: Angels Within Us Charity Concert

A new publication represents a possible small-molecule approach to potentially treat the synaptic dysfunction observed in Angelman syndrome.

Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome

David Gurzick represents FAST and the A-BOM at the 4th Chief Patient Officer’s Summit

Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program

FAST LatAm holds inaugural Angelman Syndrome Congress in Bogotá

CAN Spotlight: Go Gus Go’s 3rd Annual Golf Event

ASF & FAST Advocate for Caregivers

ASF and FAST ask the FDA to establish a Rare Disease Center of Excellence

Our Chief Operating Officer joins the White House Clinical Trials Forum

Annual Parent Meeting of the Angelman Verein and FAST Germany

FAST invited by the FDA to join advocacy-based panel discussion

INSYNC 2024 Round-Up

Introducing Dr. Edwin Weeber

CAN Spotlight: Harper's Hope Golf Scramble

FAST announces establishment of associated drug development accelerator AS²Bio

CAN Spotlight: Kettlebells for Kayleigh

FAST France - Eye Study

FAST presents at the MENA Congress for Rare Diseases Angelman Symposium

Congressional Advocacy Update

Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome

Understanding Clinical Outcome Assessments (COAs) Used in Clinical Trials

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.